Pacific Shuanglin Bio-pharmacy (000403) Fundamentals 2026 — P/E 26.6x, Revenue Analysis | SniperIQ
Pacific Shuanglin Bio-pharmacy (000403) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥9.1B, trading at ¥9.57 on the SHZ. This SniperIQ fundamentals page covers Pacific Shuanglin Bio-pharmacy's valuation (P/E 26.6x, P/B 1.4x), profitability (net margin 13.6%), revenue (¥2.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Pacific Shuanglin Bio-pharmacy's market cap?
Pacific Shuanglin Bio-pharmacy (000403) has a market capitalization of approximately ¥9.1B, trading at ¥9.57 on the SHZ. Market cap moves with the live share price.
What is Pacific Shuanglin Bio-pharmacy's P/E ratio?
Pacific Shuanglin Bio-pharmacy's trailing twelve-month P/E ratio is 26.6x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Pacific Shuanglin Bio-pharmacy?
Pacific Shuanglin Bio-pharmacy runs a net profit margin of 13.6%, a gross margin of 39.5%, and an operating margin of 16.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Pacific Shuanglin Bio-pharmacy generate?
Pacific Shuanglin Bio-pharmacy reported revenue of ¥2.6B for fiscal year 2025, with net income of ¥419M and earnings per share (EPS) of 0.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Pacific Shuanglin Bio-pharmacy pay a dividend?
Pacific Shuanglin Bio-pharmacy does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Pacific Shuanglin Bio-pharmacy financially healthy?
Pacific Shuanglin Bio-pharmacy carries a debt-to-equity ratio of 0.09x and a current ratio of 3.37x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Pacific Shuanglin Bio-pharmacy a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pacific Shuanglin Bio-pharmacy (000403) the key facts are: market cap ¥9.1B, P/E 26.6x, revenue ¥2.6B, 52-week range 8.54-19.13. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Pacific Shuanglin Bio-pharmacy's full fundamentals live
Get Pacific Shuanglin Bio-pharmacy's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.